Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.97 and traded as low as $5.85. Kura Oncology shares last traded at $6.16, with a volume of 1,985,284 shares changing hands.
Wall Street Analysts Forecast Growth
KURA has been the subject of a number of recent research reports. Barclays dropped their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. JMP Securities reiterated a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research report on Wednesday, June 4th. Finally, Mizuho dropped their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, May 19th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.50.
View Our Latest Stock Analysis on Kura Oncology
Kura Oncology Trading Up 3.2%
The business's fifty day simple moving average is $6.08 and its 200 day simple moving average is $6.97. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.02. The stock has a market cap of $550.59 million, a P/E ratio of -3.03 and a beta of 0.40.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. BVF Inc. IL boosted its stake in shares of Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after purchasing an additional 5,186,660 shares during the last quarter. Armistice Capital LLC boosted its stake in Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock worth $43,375,000 after acquiring an additional 772,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock worth $32,658,000 after acquiring an additional 129,337 shares during the last quarter. RA Capital Management L.P. bought a new position in Kura Oncology during the 4th quarter worth approximately $38,769,000. Finally, Millennium Management LLC boosted its stake in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the last quarter.
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
